- Home
- IQI vs ALT Comparison
IQI vs ALT Comparison
Compare IQI & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IQI | ALT |
|---|---|---|
| Founded | 1992 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.5M | 576.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IQI | ALT |
|---|---|---|
| Price | $10.06 | $5.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.33 |
| AVG Volume (30 Days) | 162.1K | ★ 3.5M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.05 | $2.90 |
| 52 Week High | $10.00 | $9.59 |
Technical Indicators
Market Signals| Indicator | IQI | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 55.99 | 61.41 |
| Support Level | $10.01 | $5.03 |
| Resistance Level | $10.14 | $5.83 |
| Average True Range (ATR) | 0.06 | 0.38 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 68.00 | 47.00 |
Price Performance
Historical ComparisonAbout IQI Invesco Quality Municipal Income Trust
Invesco Quality Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide current income which is exempt from federal income tax.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.